Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients "REGENESIS-LED"

Terminated

Phase 2 Results

Summary of Purpose

The purpose of this study is: - To assess the neurological outcome in acute ischemic stroke patients treated with NTx®-265, when compared with patients given a placebo control. - To assess the safety and tolerability of NTx®-265 when given to acute ischemic stroke patients. Trial Stopped: Slow Enrollment

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 24 November 2011.

1 Aug 2009 9 Jul 2009 1 Apr 2010 1 Apr 2010 1 Nov 2011 1 Sep 2011
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions See All

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Investigator)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

  • Yan Yang CCRP Clinical Research Associate Stem Cell Therapeutics Corp. Suite 1000, 1520 - 4th Street SW Calgary, Alberta, Canada T2R 1H5 Tel: 403.245.5495 ext 227 Fax: 403.245.5411 email: yyang@stemcellthera.com

    scramer@uci.edu